In 2002, Siebert wrote a letter to the United States Congress in which he objected to bill H.R. 5607 introduced by Rep. Joe Baca (D-California) which sought to place Salvia divinorum in Schedule I of the Controlled Substances Act.
One is the INCB schedules (four schedules numbered I-IV), while another is the United States' Controlled Substances Act schedules of controlled substances (five schedules, numbered I-V).
As a Schedule I drug under the federal Controlled Substances Act of 1970, marijuana (cannabis) is considered to have "no accepted medical use" and have a high potential for abuse and physical and/or emotional dependence.
Cannabis sativa has not been grown legally in the United States since the passage of the Controlled Substances Act.
Act of Parliament | Act | Statute Law Revision Act 1948 | Statute Law Revision Act 1888 | Act of Congress | Reform Act 1832 | Patient Protection and Affordable Care Act | Endangered Species Act | Digital Millennium Copyright Act | Clean Water Act | American Recovery and Reinvestment Act of 2009 | National School Lunch Act | Statute Law Revision Act 1863 | Criminal Justice Act 1988 | Local Government Act 1972 | Americans with Disabilities Act of 1990 | Racketeer Influenced and Corrupt Organizations Act | Communications Act 2003 | Statute Law Revision Act 1887 | Consumer Credit Act 1974 | ACT | Stamp Act | Official Secrets Act 1989 | National Firearms Act | act | Statute Law Revision Act 1867 | Controlled-access highway | Statute Law Revision Act 1950 | Protection from Harassment Act 1997 | Official Secrets Act 1911 |
On account of its relation to the MDxx chemical class, MDP2P, as well as safrole and isosafrole, are in the United States (U.S.) Drug Enforcement Administration (DEA) List I of Chemicals of the Controlled Substances Act (CSA) via the Chemical Diversion and Trafficking Act (CDTA).
While the Controlled Substances Act was being drafted in a House committee in 1970, Assistant Secretary of Health Roger O. Egeberg had recommended that marijuana temporarily be placed in Schedule I, the most restrictive category of drugs, pending the Commission's report.